Mouse Anti-NUTM1 Recombinant Antibody (2B6) (CBMAB-N0572-WJ)

Cheng, M. L., Huang, Y., Luong, N., LoPiccolo, J., Nishino, M., Sholl, L. M., ... & French, C. A. (2023). Exceptional response to bromodomain and extraterminal domain inhibitor therapy with BMS-986158 in BRD4-NUTM1 NUT carcinoma harboring a BRD4 splice site mutation. JCO Precision Oncology, 7, e2200633.

Van Treeck, B. J., Thangaiah, J. J., Torres-Mora, J., Stevens, T. M., Rothermundt, C., Fassan, M., ... & Folpe, A. L. (2021). NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Modern Pathology, 34(8), 1547-1557.

Boer, J. M., Valsecchi, M. G., Hormann, F. M., Antić, Ž., Zaliova, M., Schwab, C., ... & Pieters, R. (2021). Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia, 35(10), 2978-2982.

Luo, W., Stevens, T. M., Stafford, P., Miettinen, M., Gatalica, Z., & Vranic, S. (2021). NUTM1-rearranged neoplasms—a heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations—an updated review. Current Oncology, 28(6), 4485-4503.

Parra, O., Kerr, D. A., Bridge, J. A., Loehrer, A. P., & Linos, K. (2021). A case of YAP1 and NUTM1 rearranged porocarcinoma with corresponding immunohistochemical expression: review of recent advances in poroma and porocarcinoma pathogenesis with potential diagnostic utility. Journal of cutaneous pathology, 48(1), 95-101.

McEvoy, C. R., Fox, S. B., & Prall, O. W. (2020). Emerging entities in NUTM1‐rearranged neoplasms. Genes, Chromosomes and Cancer, 59(6), 375-385.

Chien, Y. W., Hsieh, T. H., Chu, P. Y., Hsieh, S. M., Liu, M. L., Lee, J. C., ... & Kao, Y. C. (2019). Primary malignant epithelioid and rhabdoid tumor of bone harboring ZNF532‐NUTM1 fusion: the expanding NUT cancer family. Genes, Chromosomes and Cancer, 58(11), 809-814.

Stevens, T. M., Morlote, D., Xiu, J., Swensen, J., Brandwein-Weber, M., Miettinen, M. M., ... & Bridge, J. A. (2019). NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum. Modern Pathology, 32(6), 764-773.

Le Loarer, F., Pissaloux, D., Watson, S., Godfraind, C., Galmiche-Rolland, L., Silva, K., ... & Tirode, F. (2019). Clinicopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas. The American journal of surgical pathology, 43(2), 268-276.

Sekine, S., Kiyono, T., Ryo, E., Ogawa, R., Wakai, S., Ichikawa, H., ... & Mori, T. (2019). Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. The Journal of clinical investigation, 129(9), 3827-3832.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols